Thermo Fisher Scientific Inc. completed the acquisition of Solventum's Purification & Filtration business for approximately $4.0 billion in cash.
The acquisition strengthens Thermo Fisher's bioproduction offerings with advanced filtration technologies.
The acquired business is expected to generate around $750 million in revenue for the full year 2025.
Acquisition Details
Thermo Fisher acquired Solventum's Purification & Filtration business for around $4.0 billion in cash.
Revenue Expectation
The acquired business is projected to generate about $750 million in revenue for the year 2025.
Strategic Impact
The acquisition enhances Thermo Fisher's portfolio in bioprocessing and adjacent markets with advanced filtration technologies.
- The acquisition adds highly complementary technologies to Thermo Fisher's portfolio, particularly in bioprocessing filtration and industrial filtration.
- Thermo Fisher expects mid- to high-single digit organic growth and strong margin expansion in the Filtration and Separation business while realizing significant synergies.
- The transaction is expected to be dilutive to adjusted earnings per share by $0.06 in the first year of ownership but aims for double-digit internal rate of return in the long term.
Thermo Fisher's acquisition of Solventum's Purification & Filtration business marks a strategic move to strengthen its presence in key markets and enhance its capabilities in filtration technologies.